Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death

Neurobiology of Disease

Volumn 50, Issue 1, 2013, Pages 160-170

  Conforti, Paola ^a   Camnasio, Stefano ^a   Mutti, Cesare ^a   Valenza, Marta ^a   Thompson, Morgan ^b   Fossale, Elisa ^b   Zeitlin, Scott ^c   MacDonald, Marcy E ^b   Zuccato, Chiara ^a   Cattaneo, Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Huntington's disease; Mouse knock in neural stem cells; Neuronal differentiation; PolyQ

Indexed keywords

ADENOSINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CELL PROTEIN; CYTOSINE; GUANOSINE; HUNTINGTIN; MESSENGER RNA; NESTIN; POLYGLUTAMINE; PROTEIN BLBP; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE PARAMETERS; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE TARGETING; GLIA CELL; HETEROZYGOSITY; HTT GENE; HUNTINGTON CHOREA; IN VITRO STUDY; MOUSE; MUTATIONAL ANALYSIS; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NEURAL STEM CELL; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; TRINUCLEOTIDE REPEAT; WILD TYPE;

ANIMALS; CELL DIFFERENTIATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCK-IN TECHNIQUES; GENE KNOCKOUT TECHNIQUES; HUNTINGTON DISEASE; MICE; NERVE TISSUE PROTEINS; NEURAL STEM CELLS; NEUROGLIA; NEURONS; NUCLEAR PROTEINS; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRINUCLEOTIDE REPEATS;

EID: 84868507542     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.10.015     Document Type: Article

References (59)

1. Apostol B.L., et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol. Cell. Neurosci. 2008, 39:8-20.
2. Camnasio S., et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol. Dis. 2012, 46:41-51.
3. Cattaneo E., et al. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. 2001, 24:182-188.
4. Cattaneo E., et al. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 2005, 6:919-930.
5. Conforti P., et al. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol. Cell. Neurosci. 2008, 39:1-7.
6. Conti L., Cattaneo E. Neural stem cell systems: physiological players or in vitro entities?. Nat. Rev. Neurosci. 2010, 11:176-187.
7. Conti L., et al. Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol. 2005, 3:e283.
8. Cooper J.K., et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet. 1998, 7:783-790.
9. Cummings D.M., et al. A critical windows of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease. J. Neurophysiol. 2012, 107:677-691.
10. Diaferia G., et al. Systematic chromosomal analysis of cultured mouse neural stem cell lines. Stem Cells Dev. 2011, 20:1411-1423.
11. Diekmann H., et al. Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish. J. Neurosci. 2009, 29:1343-1349.
12. Dragatsis I., et al. CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol. Dis. 2009, 33:315-330.
13. Duyao M.P., et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995, 269:407-410.
14. Garavaglia A., et al. Adaptation of NS cells growth and differentiation to high-throughput screening-compatible plates. BMC Neurosci. 2010, 11:7.
15. Gines S., et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet. 2003, 12:497-508.
16. Godin J.D., et al. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 2010, 67:392-406.
17. Goffredo D., et al. Setting the conditions for efficient, robust and reproducible generation of functionally active neurons from adult subventricular zone-derived neural stem cells. Cell Death Differ. 2008, 15:1847-1856.
18. Graham R.K., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
19. Hackam A.S., et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell Biol. 1998, 141:1097-1105.
20. HDCRG A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
21. Hermel E., et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ. 2004, 11:424-438.
22. Jacobsen J.C., et al. HD CAG-correlated gene expression changes support a simple dominant gain of function. Hum. Mol. Genet. 2011, 20:2846-2860.
23. Karasinska J.M., et al. Cholesterol metabolism in Huntington disease. Nat. Rev. Neurol. 2011, 7:561-572.
24. Kock P., et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 2011, 480:543-546.
25. Liu Y.F. Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J. Biol. Chem. 1998, 273:28873-28877.
26. Liu Y.F., et al. Activation of MLK2-mediated signaling cascades by polyglutamine-expanded huntingtin. J. Biol. Chem. 2000, 275:19035-19040.
27. Lo Sardo V., et al. An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin. Nat. Neurosci. 2012, 15:713-721.
28. Martindale D., et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet. 1998, 18:150-154.
29. Menalled L.B., et al. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 2003, 465:11-26.
30. Molero A.E., et al. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:21900-21905.
31. Morton A.J., et al. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis. 2009, 33:331-341.
32. Niclis J., et al. Human embryonic stem cell models of Huntington disease. Reprod. Biomed. Online 2009, 19:106-113.
33. Park I.H., et al. Disease-specific induced pluripotent stem cells. Cell. 2008, 134:877-886.
34. Pollard S.M., et al. Adherent neural stem (NS) cells from fetal and adult forebrain. Cereb. Cortex 2006, 16(Suppl. 1):i112-i120.
35. Pouladi M.A., et al. NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2012, 48:282-289.
36. Reiner A., et al. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:5733-5737.
37. Rigamonti D., et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 2000, 20:3705-3713.
38. Rigamonti D., et al. Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators. J. Biol. Chem. 2007, 282:24554-24562.
39. Ritch J.J., et al. Multiple phenotypes in Huntington disease mouse neural stem cells. Mol. Cell. Neurosci. 2012, 50:70-81.
40. Robinton D.A., Daley G.Q. The promise of induced pluripotent stem cells in research and therapy. Nature 2012, 481:295-305.
41. Rubin L.L., et al. Stem cell biology and drug discovery. BMC Biol. 2011, 9:42.
42. Sipione S., Cattaneo E. Modeling brain pathologies using neural stem cells. Methods Mol. Biol. 2002, 198:245-262.
43. Sipione S., et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Mol. Genet. 2002, 11:1953-1965.
44. Soldati C., et al. Rescue of gene expression by modified REST decoy oligonucleotides in a cellular model of Huntington's disease. J. Neurochem. 2011, 116:415-425.
45. Spiliotopoulos D., et al. An optimized experimental strategy for efficient conversion of embryonic stem (ES)-derived mouse neural stem (NS) cells into a nearly homogeneous mature neuronal population. Neurobiol. Dis. 2009, 34:320-331.
46. The Hd iPSC Consortium Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 2012, 11:264-278.
47. Trettel F., et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 2000, 9:2799-2809.
48. Valenza M., Cattaneo E. Emerging roles for cholesterol in Huntington's disease. Trends Neurosci. 2011, 34:474-486.
49. Varma H., et al. Selective inhibitors of death in mutant huntingtin cells. Nat. Chem. Biol. 2007, 3:99-100.
50. Wheeler V.C., et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 1999, 8:115-122.
51. Ying Q.L., et al. Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. Nat. Biotechnol. 2003, 21:183-186.
52. Zeitlin S., et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 1995, 11:155-163.
53. Zhang Y., et al. Huntingtin inhibits caspase-3 activation. EMBO J. 2006, 25:5896-5906.
54. Zhang N., et al. Characterization of Human Huntington's Disease Cell Model from Induced Pluripotent Stem Cells. PLoS Curr. 2010, 2:RRN1193.
55. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 2009, 5:311-322.
56. Zuccato C., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
57. Zuccato C., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 2003, 35:76-83.
58. Zuccato C., et al. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J. Neurosci. 2007, 27:6972-6983.
59. Zuccato C., et al. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.